AZA group (n=43) CYC group (n=72)
p
AZA dose, mg/day 101.78±32.22 na
Total cumulative CYC dose, mg na 8241±6190
Combination of medium-high dose corticosteroids** 65.1% 51.4% 0.176
ΔMMRC score 0 (-1 to 1) 0 (-1 to 0) 0.031
ΔFCV, ml 0.01 (-0.27 to 0.16) 0.06 (-0.68 to 1.5) 0.091
ΔFCV, predicted % -1 (-6 to 3) 3 (-2.75 to 5 ) 0.025
Δ percent reticulation on HRCT 0 (-0.62 to 1.25) 0 (-5 to 0) 0.075
Number of patients with ILD progression 17 (39.5%) 11 (15.3%) 0.013
5-year survival 91% 95% 0.138
Disease specific evaluations, % progression Disease specific evaluations, % progression Disease specific evaluations, % progression Disease specific evaluations, % progression
SSc (n=47) 60 11.9 0.029
RA (n=16) 62.5 25 >0.05
pSS (n=16) 71.4 11.1 0.035
IMS (n=14) 11.1 - >0.05
IPAF(n=20) 26.6 23.1 >0.05